Cargando…

Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients

BACKGROUND: In this prospective study, we aimed to assess the haemodynamic changes before and after haemodialysis (HD) in cardiac healthy subjects on chronic HD by imaging methods and endocrine markers of fluid balance. METHODS: Mid-regional pro-atrial natriuretic peptide (MR-proANP), N-terminal pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasche, Franz Maximilian, Stoebe, Stephan, Ebert, Thomas, Feige, Silvana, Hagendorff, Andreas, Rasche, Wilma Gertrud, Barinka, Filip, Busch, Volker, Sack, Ulrich, Schneider, Jochen G., Schiekofer, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450351/
https://www.ncbi.nlm.nih.gov/pubmed/28558715
http://dx.doi.org/10.1186/s12882-017-0589-3
_version_ 1783239951697051648
author Rasche, Franz Maximilian
Stoebe, Stephan
Ebert, Thomas
Feige, Silvana
Hagendorff, Andreas
Rasche, Wilma Gertrud
Barinka, Filip
Busch, Volker
Sack, Ulrich
Schneider, Jochen G.
Schiekofer, Stephan
author_facet Rasche, Franz Maximilian
Stoebe, Stephan
Ebert, Thomas
Feige, Silvana
Hagendorff, Andreas
Rasche, Wilma Gertrud
Barinka, Filip
Busch, Volker
Sack, Ulrich
Schneider, Jochen G.
Schiekofer, Stephan
author_sort Rasche, Franz Maximilian
collection PubMed
description BACKGROUND: In this prospective study, we aimed to assess the haemodynamic changes before and after haemodialysis (HD) in cardiac healthy subjects on chronic HD by imaging methods and endocrine markers of fluid balance. METHODS: Mid-regional pro-atrial natriuretic peptide (MR-proANP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), vasopressin (AVP) and copeptin (CT-proAVP), metanephrines and normetanephrines, renin and aldosterone, standard transthoracic echocardiography and diameter of vena cava inferior (VCID) were performed in 20 patients with end stage renal disease (CKD5D) before and after HD and were stratified in residual excretion (RE, less or more 0.5 l) and ultrafiltration rate (UF, less or more 2 l). RESULTS: Copeptin was significantly higher in patients before HD. Copeptin was inversely correlated with haemodialysis treatment adequacy (KT/v), RE and UF, but was not significantly influenced by age, gender and body mass index (BMI). MR-proANP was significantly reduced by haemodialysis by 27% and was inversely correlated with KT/v, but there was a significant influence by UF, RE, age, gender and BMI. NT-proBNP was significantly higher in patients before HD and was not influenced by RE and UF. Renin, aldosterone, metanephrines and normetanephrines did not demonstrate significant differences. Echocardiographic parameters and VCID were significantly correlated with RE, UF and copeptin. CONCLUSION: Modern biomarkers will provide cardiovascular risk assessment, but elimination (UF), RE and other factors may influence the serum concentrations, e.g. in patients with renal impairment. The interpretation will be limited by altered reference ranges, and will be restricted to individual courses combined with clinical and echocardiographic data. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0589-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5450351
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54503512017-06-01 Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients Rasche, Franz Maximilian Stoebe, Stephan Ebert, Thomas Feige, Silvana Hagendorff, Andreas Rasche, Wilma Gertrud Barinka, Filip Busch, Volker Sack, Ulrich Schneider, Jochen G. Schiekofer, Stephan BMC Nephrol Research Article BACKGROUND: In this prospective study, we aimed to assess the haemodynamic changes before and after haemodialysis (HD) in cardiac healthy subjects on chronic HD by imaging methods and endocrine markers of fluid balance. METHODS: Mid-regional pro-atrial natriuretic peptide (MR-proANP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), vasopressin (AVP) and copeptin (CT-proAVP), metanephrines and normetanephrines, renin and aldosterone, standard transthoracic echocardiography and diameter of vena cava inferior (VCID) were performed in 20 patients with end stage renal disease (CKD5D) before and after HD and were stratified in residual excretion (RE, less or more 0.5 l) and ultrafiltration rate (UF, less or more 2 l). RESULTS: Copeptin was significantly higher in patients before HD. Copeptin was inversely correlated with haemodialysis treatment adequacy (KT/v), RE and UF, but was not significantly influenced by age, gender and body mass index (BMI). MR-proANP was significantly reduced by haemodialysis by 27% and was inversely correlated with KT/v, but there was a significant influence by UF, RE, age, gender and BMI. NT-proBNP was significantly higher in patients before HD and was not influenced by RE and UF. Renin, aldosterone, metanephrines and normetanephrines did not demonstrate significant differences. Echocardiographic parameters and VCID were significantly correlated with RE, UF and copeptin. CONCLUSION: Modern biomarkers will provide cardiovascular risk assessment, but elimination (UF), RE and other factors may influence the serum concentrations, e.g. in patients with renal impairment. The interpretation will be limited by altered reference ranges, and will be restricted to individual courses combined with clinical and echocardiographic data. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0589-3) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-30 /pmc/articles/PMC5450351/ /pubmed/28558715 http://dx.doi.org/10.1186/s12882-017-0589-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rasche, Franz Maximilian
Stoebe, Stephan
Ebert, Thomas
Feige, Silvana
Hagendorff, Andreas
Rasche, Wilma Gertrud
Barinka, Filip
Busch, Volker
Sack, Ulrich
Schneider, Jochen G.
Schiekofer, Stephan
Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
title Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
title_full Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
title_fullStr Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
title_full_unstemmed Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
title_short Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
title_sort modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450351/
https://www.ncbi.nlm.nih.gov/pubmed/28558715
http://dx.doi.org/10.1186/s12882-017-0589-3
work_keys_str_mv AT raschefranzmaximilian modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT stoebestephan modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT ebertthomas modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT feigesilvana modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT hagendorffandreas modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT raschewilmagertrud modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT barinkafilip modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT buschvolker modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT sackulrich modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT schneiderjocheng modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients
AT schiekoferstephan modernpeptidebiomarkersandechocardiographyincardiachealthyhaemodialysispatients